OncoMatch/Clinical Trials/NCT06720324
CD7-specific CAR-T Cell in the Treatment of CD7-positive Relapsed/Refractory Hematologic Tumors
Is NCT06720324 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies Fludarabine + Cyclophosphamide + CD7-specific CAR-T Cells for hematologic malignancy.
Treatment: Fludarabine + Cyclophosphamide + CD7-specific CAR-T Cells — This study is a single-center, open, prospective single-arm clinical study of patients with CD7 postive relapsed / refractoryhematological tumors to evaluate the safety and efficacy of CD7-specific CAR-T cells in relapsed / refractory hematological tumors while collecting pharmacokinetics and pharmacodynamics indicators of CAR-T cells.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Multiple Myeloma
Myelodysplastic Syndrome
Chronic Lymphocytic Leukemia
Biomarker criteria
Required: CD7 expression
bone marrow flow cytometry detected tumor cells as CD7 expression and/or pathological immunohistochemistry of extramedullary lesions was confirmed that tumor cells expressed CD7
Required: CD4 negative
the immunophenotype of tumor cell surface at the time of flow cytometry detection should be CD4 and CD8 negative
Required: CD8 negative
the immunophenotype of tumor cell surface at the time of flow cytometry detection should be CD4 and CD8 negative
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Lab requirements
Kidney function
serum creatinine ≤ 1.5× uln
Liver function
total bilirubin ≤ 1.5×uln; alt and ast ≤2.5×uln
Cardiac function
left ventricular ejection fraction (lvef) ≥50%; baseline peripheral oxygen saturation > 90%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify